Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
EXAS 
EXACT Sciences Corporation (EXAS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: EXAS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -22.69% | Avg. Invested days 38 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.91B USD | Price to earnings Ratio - | 1Y Target Price 68.86 |
Price to earnings Ratio - | 1Y Target Price 68.86 | ||
Volume (30-day avg) 2938097 | Beta 0.98 | 52 Weeks Range 39.97 - 72.83 | Updated Date 06/18/2025 |
52 Weeks Range 39.97 - 72.83 | Updated Date 06/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.51 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -36.06% | Operating Margin (TTM) -11.53% |
Management Effectiveness
Return on Assets (TTM) -1.83% | Return on Equity (TTM) -36.89% |
Valuation
Trailing PE - | Forward PE 2500 | Enterprise Value 11608404804 | Price to Sales(TTM) 3.49 |
Enterprise Value 11608404804 | Price to Sales(TTM) 3.49 | ||
Enterprise Value to Revenue 4.1 | Enterprise Value to EBITDA 215.11 | Shares Outstanding 188638000 | Shares Floating 186841842 |
Shares Outstanding 188638000 | Shares Floating 186841842 | ||
Percent Insiders 0.89 | Percent Institutions 98.52 |
Analyst Ratings
Rating 4.54 | Target Price 68.81 | Buy 6 | Strong Buy 17 |
Buy 6 | Strong Buy 17 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
EXACT Sciences Corporation
Company Overview
History and Background
EXACT Sciences Corporation was founded in 1995. Initially focused on detecting colorectal cancer through DNA analysis of stool samples, the company's evolution involved significant R&D and strategic acquisitions, solidifying its position in cancer diagnostics.
Core Business Areas
- Screening: Focuses on early cancer detection through non-invasive testing, including Cologuard for colorectal cancer screening.
- Precision Oncology: Development and commercialization of genomic tests to guide cancer treatment decisions. This includes Oncotype DX, a breast cancer recurrence score test.
- Multi-Cancer Early Detection: Focuses on development of a blood based multi-cancer early detection (MCED) test
Leadership and Structure
The leadership team consists of Kevin Conroy (Chairman and CEO). The organizational structure includes departments focused on R&D, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Cologuard: A non-invasive, stool-based DNA screening test for colorectal cancer. It is a major source of revenue. Estimated market share in colorectal cancer screening is approximately 35-40% in the US. Competitors include fecal immunochemical tests (FIT), colonoscopy, and sigmoidoscopy. Revenue in 2023 was approximately $1.68 billion.
- Oncotype DX: A genomic test that predicts the likelihood of breast cancer recurrence and the benefit from chemotherapy. Competitors include MammaPrint. Revenue in 2023 was approximately $539 million.
- OncoExTra: A comprehensive genomic profiling test that helps physicians personalize treatment strategies for patients with advanced, refractory, metastatic, or recurrent cancer. Key competitors are Foundation Medicine and Caris Life Sciences.
Market Dynamics
Industry Overview
The cancer diagnostics industry is growing rapidly, driven by advancements in genomics, personalized medicine, and the increasing incidence of cancer. The industry is intensely competitive with many players working on early cancer detection and advanced diagnostic technologies.
Positioning
EXACT Sciences is a leader in non-invasive cancer screening and precision oncology, with a strong brand recognition and established commercial infrastructure. Its competitive advantages include its proprietary technology, established relationships with healthcare providers, and strong reimbursement coverage.
Total Addressable Market (TAM)
The total addressable market for cancer diagnostics is estimated to be in the tens of billions of dollars. EXACT Sciences is well-positioned to capture a significant portion of this market with its existing products and pipeline of new tests.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Established commercial infrastructure
- Proprietary technology
- Strong reimbursement coverage
- Proven track record of innovation
Weaknesses
- Reliance on a few key products
- High marketing and sales expenses
- Competition from established players
- Negative profitability
Opportunities
- Expanding into new cancer types
- Developing new diagnostic technologies
- Increasing adoption of existing tests
- Geographic expansion
- Partnerships and acquisitions
Threats
- Competition from new entrants
- Changes in reimbursement policies
- Technological obsolescence
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- GHDX
- DGX
- MTLS
Competitive Landscape
EXACT Sciences competes with established diagnostics companies, as well as smaller, emerging players. Its advantages include its strong brand, established commercial infrastructure, and proprietary technology.
Major Acquisitions
PreventionGenetics
- Year: 2021
- Acquisition Price (USD millions): 190
- Strategic Rationale: To expand EXACT Sciences' capabilities in hereditary cancer testing.
Base Genomics
- Year: 2020
- Acquisition Price (USD millions): 410
- Strategic Rationale: To enhance EXACT Sciences' R&D capabilities in methylation-based technologies for cancer diagnostics.
Growth Trajectory and Initiatives
Historical Growth: EXACT Sciences has experienced rapid revenue growth in recent years.
Future Projections: Analysts project continued revenue growth for EXACT Sciences, driven by increased adoption of its existing tests and the launch of new products.
Recent Initiatives: Recent initiatives include expanding the sales force, launching new marketing campaigns, and developing new diagnostic tests.
Summary
EXACT Sciences shows good promise in the early cancer detection and precision oncology spaces and has shown great revenue growth. The company has strong brand recognition and distribution channels for its Cologuard and Oncotype DX products. Its main challenges are achieving profitability, managing competition, and successfully launching new products. Investors should watch out for regulatory or competitive changes that could impact its long-term prospects.
Peer Comparison
Sources and Disclaimers
Data Sources:
- EXACT Sciences Corporation's SEC Filings
- Company Investor Relations
- Analyst Reports
- Industry Research Reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About EXACT Sciences Corporation
Exchange NASDAQ | Headquaters Madison, WI, United States | ||
IPO Launch date 2001-02-01 | Chairman of the Board & CEO Mr. Kevin T. Conroy J.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 6900 | Website https://www.exactsciences.com |
Full time employees 6900 | Website https://www.exactsciences.com | ||
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.